4YZN

Humanized Roco4 bound to Compound 19


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free: 0.216 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.189 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Structural Characterization of LRRK2 Inhibitors.

Gilsbach, B.K.Messias, A.C.Ito, G.Sattler, M.Alessi, D.R.Wittinghofer, A.Kortholt, A.

(2015) J Med Chem 58: 3751-3756

  • DOI: https://doi.org/10.1021/jm5018779
  • Primary Citation of Related Structures:  
    4YZM, 4YZN

  • PubMed Abstract: 

    Kinase inhibition is considered to be an important therapeutic target for LRRK2 mediated Parkinson's disease (PD). Many LRRK2 kinase inhibitors have been reported but have yet to be optimized in order to qualify as drug candidates for the treatment of the disease. In order to start a structure-function analysis of such inhibitors, we mutated the active site of Dictyostelium Roco4 kinase to resemble LRRK2. Here, we show saturation transfer difference (STD) NMR and the first cocrystal structures of two potent in vitro inhibitors, LRRK2-IN-1 and compound 19, with mutated Roco4. Our data demonstrate that this system can serve as an excellent tool for the structural characterization and optimization of LRRK2 inhibitors using X-ray crystallography and NMR spectroscopy.


  • Organizational Affiliation

    †Department of Cell Biochemistry, University of Groningen, 9747AG Groningen, The Netherlands.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Probable serine/threonine-protein kinase roco4287Dictyostelium discoideumMutation(s): 2 
Gene Names: roco4DDB_G0288251
EC: 2.7.11.1
UniProt
Find proteins for Q6XHB2 (Dictyostelium discoideum)
Explore Q6XHB2 
Go to UniProtKB:  Q6XHB2
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ6XHB2
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
4K5
Query on 4K5

Download Ideal Coordinates CCD File 
B [auth A](4-{[4-(cyclopropylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-2-fluoro-5-methoxyphenyl)(morpholin-4-yl)methanone
C20 H21 F4 N5 O3
FKNAWDCGDQUZRV-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
4K5 Binding MOAD:  4YZN IC50: 1.54e+4 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free: 0.216 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.189 
  • Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 42.4α = 90
b = 42.4β = 90
c = 326.9γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
MJFF for Parkinson ResearchNetherlands--

Revision History  (Full details and data files)

  • Version 1.0: 2015-05-06
    Type: Initial release
  • Version 1.1: 2015-05-27
    Changes: Database references
  • Version 1.2: 2016-10-19
    Changes: Refinement description
  • Version 1.3: 2024-01-10
    Changes: Data collection, Database references, Refinement description